Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.6K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

2.5K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.5K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

3.9K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.9K
Issues And Trends In Healthcare Delivery System01:29

Issues And Trends In Healthcare Delivery System

6.3K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
6.3K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The SINTER study: a recall-by-genotype design with multidimensional musculoskeletal phenotyping across internal-medicine outpatient clinics.

European journal of epidemiology·2026
Same author

Secondary Erythrocytosis in Patients With Heart Failure on SGLT2 Inhibitors: Insights from a Multicenter "Real World" Study.

The American journal of cardiology·2025
Same author

The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the Netherlands.

Journal of clinical & translational endocrinology·2024
Same author

Clinical Translation and Implementation of a Bioartificial Pancreas Therapy: A Qualitative Study Exploring the Perspectives of People With Type 1 Diabetes.

Transplantation direct·2024
Same author

The Effect of <i>Sargassum fusiforme</i> and <i>Fucus vesiculosus</i> on Continuous Glucose Levels in Overweight Patients with Type 2 Diabetes Mellitus: A Feasibility Randomized, Double-Blind, Placebo-Controlled Trial.

Nutrients·2024
Same author

Apolipoprotein-CIII O-Glycosylation Is Associated with Micro- and Macrovascular Complications of Type 2 Diabetes.

International journal of molecular sciences·2024

Related Experiment Video

Updated: Feb 22, 2026

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber
09:07

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber

Published on: June 11, 2020

5.8K

[Advanced diabetes technology: clinical application and practical implications].

Rowan V Toet1,2, Behiye Özcan1, Mandy van Hoek1

  • 1Erasmus MC, afd. Interne geneeskunde, Rotterdam.

Nederlands Tijdschrift Voor Geneeskunde
|February 20, 2026
PubMed
Summary

Advanced diabetes technologies like continuous glucose monitoring (CGM) and hybrid closed-loop (HCL) systems improve glycemic control and quality of life. Personalized implementation is key for optimizing outcomes in diabetes management.

More Related Videos

Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms
08:16

Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms

Published on: March 15, 2024

2.2K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.4K

Related Experiment Videos

Last Updated: Feb 22, 2026

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber
09:07

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber

Published on: June 11, 2020

5.8K
Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms
08:16

Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms

Published on: March 15, 2024

2.2K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.4K

Area of Science:

  • Endocrinology
  • Medical Technology

Background:

  • Diabetes mellitus is a chronic condition significantly impacting quality of life.
  • Traditional treatments include insulin injections and self-monitoring.
  • Technological advancements offer new avenues for glycemic control.

Purpose of the Study:

  • To review the impact of modern diabetes technologies on glycemic control and patient outcomes.
  • To highlight the benefits of continuous glucose monitoring (CGM), insulin pumps, and hybrid closed-loop (HCL) systems.
  • To discuss the importance of personalized implementation of these technologies.

Main Methods:

  • Review of clinical evidence on diabetes management technologies.
  • Analysis of outcomes including HbA1c, Time in Range (TIR), and hypoglycemia.
  • Consideration of patient-specific factors for technology adoption.

Main Results:

  • CGM, HCL systems, and connected devices reduce HbA1c and increase TIR.
  • These technologies lower the risk of severe hypoglycemia.
  • Improved quality of life and psychosocial outcomes are associated with technology use.

Conclusions:

  • Diabetes technology offers significant benefits for glycemic control and well-being.
  • Tailored implementation considering patient factors is crucial for success.
  • Clinicians must stay informed about evolving technologies for effective diabetes care.